ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated December 21, 2020 with regard to loss of share certificate of the Company published in Financial Express21-12-2020
21-12-2020
USFDA allows fast track development for Zydus' liver drug Saroglitazar
The drug aims to control Alkaline Phosphotase (ALP) or bilirubin, reduces strong side effects of existing drugs such as pruritus or increase in LDL-cholesterol and brings in better tolerance and efficacy09-12-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Revised Half Yearly Disclosure Of Related Party Transaction On Consolidated Basis.
Revised Half Yearly Disclosure Of Related Party Transaction On Consolidated Basis.27-11-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Half Yearly Disclosure Of Related Party Transaction On Consolidated Basis.
Half Yearly disclosure of Related Party Transaction on Consolidated basis.12-11-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure under SEBI PIT Regulation with regard to purchase of shares of the Company.06-11-2020
Buy Zydus Wellness: target of Rs 2300: Sharekhan
Sharekhan is bullish on Zydus Wellness recommended buy rating on the stock with a target price of Rs 2300 in its research report dated November 02, 2020.05-11-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of unaudited financial results of the Company.04-11-2020
Zydus Wellness Q2 net loss widens to Rs 105.34 crore
Total income stood at Rs 344.80 crore for the reported quarter, up 4.49 percent compared to Rs 329.98 crore for the same period a year ago, Zydus Wellness said in a BSE filing.02-11-2020
Earnings Call for Q2FY21 of Zydus Wellness
Conference Call with Zydus Wellness Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.02-11-2020
ZYDUS WELLNESS LTD.-$ - 531335 - Unaudited Financial Results For The Quarter/Half Year Ending September 30, 2020
Unaudited Financial Results for the Quarter/half year ending September 30, 202002-11-2020